[1] AACR Clinical Trials Plenary Session. Retrieved April 1, 2022, from https://www.abstractsonline.com/pp8/#!/10517/sessions/@sessiontype=Clinical%20Trials%20Plenary%20Session/1 [2] Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma. Retrieved April ...
[2]CT076/4 - Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis ;https://www.abstractsonline.com/pp8/#!/10828/presentation/10419....
1.https://www.abstractsonline.com/pp8/#!/10517/presentation/17990 2.https://www.abstractsonline.com/pp8/#!/10517/presentation/14669 3.生物世界《启函生物首次公布NK细胞疗法临床前数据,抗血液瘤和实体瘤效果出色》 声明:本...
CT022 - CheckMate 848: A randomized,open-label, phase 2 study ofnivolumabin combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.AACR 2022, abstr.CT022 https://www.abstractsonline.com/pp8/#!/10517/presentation/19...
R. Murciano-Goroff, Rebecca S. Heist, Yasutoshi Kuboki, Takafumi Koyama,et al.CT028 - A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors. Presented at AACR 2023.https://www.abstracts...
[3] Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects. Retrieved April 12, 2022, from https://www.abstractsonline.com/pp8/#!/10517/presentation/...
https://www.abstractsonline.com/pp8/#!/10517/presentation/18034 访问 关于普米斯 普米斯于2018年注册成立,一直秉承“点亮创新火种,成就健康人生”的创业使命,聚焦恶性肿瘤及自身免疫疾病,致力于国家1类创新生物药的研发及产业化。核心团队具有务实的国内外创新生物药研发、药政策略、产业化和商业化经验,正在推进超过...
Yilong Wu, Meijuan Huang, Yanqiu Zhaoet al. CT102 / 10 - Interim results of a first-in-human, dose escalation and expansion study of PLB-1004, an irreversible inhibitor of exon 20 insertion mutations in patients with non-small cell lung cancer.Presented at AACR2023.https://www.abstracts...
, March 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the acceptance of two abstracts for presentation at the upcoming American Association for Cancer Resea...
https://www.abstractsonline.com/pp8/#!/10828/presentation/10298 [2]Shun Lu, Qiming Wang, Lin Wu, Ligang Xing,et al. CT201 / 14 - HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients. Presented at AACR ...